background
felin
leukaemia
viru
felv
pathogen
caus
fatal
ill
cat
worldwid
high
demand
product
protect
diseas
durat
immun
provid
inactiv
felv
vaccin
versifel
felv
administ
cat
target
age
determin
kitten
receiv
two
vaccin
age
week
old
subsequ
challeng
month
later
felva
glasgow
isol
result
studi
younger
age
control
kitten
show
persist
felv
antigenaemia
confirm
challeng
viru
sever
efficaci
contrast
control
cat
show
requir
level
persist
antigenaemia
maximum
cat
affect
middl
durat
studi
longer
studi
howev
apart
one
anim
short
durat
studi
cat
vaccin
versifel
felv
neg
persist
antigenaemia
consid
treatment
success
conclus
conclus
shown
although
agerel
resist
infect
virul
felv
challeng
evid
earli
month
age
vaccin
versifel
felv
may
aid
protect
cat
felv
relat
diseas
three
year
primari
vaccin
kitten
felin
leukaemia
viru
felv
gammaretroviru
signific
pathogen
domest
cat
throughout
world
also
small
felid
wildcat
lynx
contact
saliva
main
mode
transmiss
although
faec
also
shown
contain
viru
shed
infect
cat
cat
expos
felv
may
becom
either
persist
viraem
recov
infect
young
cat
rapidli
infect
follow
contact
exposur
third
categori
cat
infect
felv
latent
infect
viraem
covert
infect
develop
felv
diseas
viraem
anim
respond
felv
antigen
show
limit
respons
viru
result
higher
risk
develop
fatal
diseas
cat
recov
infect
produc
viru
neutralis
antibodi
consid
import
prevent
reinfect
pass
colostrum
protect
neonat
kitten
antibodi
felin
oncornavirusassoci
cell
membran
antigen
focma
also
induc
protect
develop
felvrel
neoplast
diseas
addit
antibodymedi
respons
role
cellmedi
immun
respons
may
also
involv
protect
felv
still
signific
pathogen
domest
cat
worldwid
clear
demand
method
protect
infect
virusrel
diseas
previou
studi
review
spark
examin
protect
cat
infect
afford
vaccin
varieti
commerci
vaccin
shown
vari
consider
efficaci
anoth
studi
examin
protect
cat
felv
challeng
follow
vaccin
show
durat
immun
last
least
month
follow
primari
cours
present
data
three
separ
clinic
studi
examin
protect
felvrel
diseas
month
primari
vaccin
regimen
three
separ
studi
conduct
establish
two
treatment
group
control
vaccin
high
level
age
relat
resist
challeng
report
third
group
young
kitten
ad
studi
immedi
prior
challeng
order
valid
challeng
viru
titr
associ
regimen
studi
utilis
randomis
complet
block
design
tabl
illustr
studi
design
anim
examin
presenc
felv
antigen
sera
collect
weekli
three
week
challeng
week
challeng
studi
run
contract
research
organis
univers
lyon
franc
compli
institut
oper
procedur
appropri
anim
welfar
legisl
separ
pfizer
ethic
review
process
anim
specifi
pathogen
free
european
mix
breed
cat
day
age
day
group
day
old
group
prior
challeng
obtain
commerci
breeder
cat
equal
split
male
femal
treatment
group
cat
routin
test
elisa
presenc
absenc
antibodi
follow
pathogenscaliciviru
fiv
felv
infecti
periton
viral
rhinotrach
panleukopenia
intestin
coronaviru
rotavirusbi
commerci
diagnost
laboratori
use
proprietari
assay
analyt
method
studi
anim
neg
felv
antigen
antifocma
antibodi
prior
vaccin
also
prior
challeng
vaccin
use
experiment
serial
versifel
felv
contain
inactiv
felin
leukaemia
viru
minimum
dose
proprietari
adjuv
system
prior
administr
viral
challeng
suffici
volum
frozen
felva
glasgow
isol
stock
mean
titr
x
ffuml
thaw
steril
contain
felv
challeng
suspens
administr
cat
prepar
dilut
stock
viru
target
concentr
x
ffuml
use
steril
dmem
hepe
buffer
diluent
site
intraperiton
inject
caudolater
aspect
right
ventral
abdomen
use
separ
prepar
steril
syring
needl
cat
take
care
avoid
punctur
intern
organ
intestin
ml
felv
challeng
suspens
inject
caudolater
periton
caviti
anim
group
cat
group
receiv
ml
dose
cat
challeng
either
month
month
month
vaccin
previou
laboratori
studi
perform
author
indic
challeng
titr
volum
rout
administr
suffici
result
felv
infect
younger
anim
studi
anim
observ
least
daili
sign
distress
ill
health
addit
cat
kitten
physic
examin
prior
enrol
vaccin
applic
clinic
observ
rectal
temperatur
inject
site
measur
also
perform
follow
vaccin
also
time
sampl
collect
follow
challeng
blood
sampl
approxim
ml
occas
collect
jugular
vein
plain
tube
without
anticoagul
use
dispos
steril
needl
deem
appropri
investig
cat
could
sedat
prior
sampl
collect
baselin
blood
sampl
collect
kitten
studi
day
day
prior
challeng
three
week
challeng
commenc
blood
sampl
collect
anim
store
overnight
refriger
centrifug
follow
day
approxim
rpm
approxim
minut
per
site
standard
oper
procedur
follow
centrifug
serum
harvest
tube
divid
two
aliquot
label
store
frozen
cryogen
tube
blood
serum
sampl
collect
individu
label
one
two
aliquot
serum
despatch
contract
research
laboratori
analys
felv
petchek
felv
antigen
test
kit
idexx
per
test
kit
instruct
confirmatori
analysi
perform
highli
posit
sampl
assay
use
commerci
proprietari
technolog
publish
rel
sensit
rel
specif
presenc
antibodi
evalu
elisa
accord
test
kit
instruct
felv
antibodi
elisa
european
veterinari
laboratori
antifocma
antibodi
evalu
ifa
accord
analyt
laboratori
standard
oper
procedur
antibodi
elisa
titr
greater
consid
posit
antifocma
antibodi
titr
greater
consid
posit
assay
valid
analyt
laboratori
prior
use
studi
accord
standard
oper
procedur
conjunct
pfizer
anim
health
primari
efficaci
variabl
antigen
analysi
serum
sampl
accord
monograph
felin
leukaemia
vaccin
inactiv
summari
data
need
present
term
number
percentag
anim
persist
antigenaemia
determin
protein
treatment
group
persist
antigenaemia
anim
defin
per
pharmacopoeia
anim
posit
antigen
three
consecut
week
five
separ
occas
consecut
third
week
fifteenth
week
felv
challeng
antibodi
antifocma
antibodi
result
summaris
treatment
group
time
calcul
geometr
mean
minimum
maximum
categor
result
test
result
treatment
group
bodi
weight
day
summaris
term
mean
standard
deviat
minimum
maximum
treatment
group
rectal
temperatur
summaris
calcul
descript
statist
includ
mean
standard
deviat
minimum
maximum
treatment
group
day
geometr
mean
titr
antibodi
list
tabl
baselin
serum
sampl
cat
group
neg
felv
antigen
antibodi
ie
geometr
mean
antifocma
antibodi
ie
geometr
mean
data
shown
baselin
serum
sampl
kitten
addit
group
neg
felv
antigen
antibodi
ie
geometr
mean
antifocma
antibodi
ie
geometr
mean
data
shown
therefor
anim
fulfil
criteria
inclus
studi
defin
european
pharmacopeia
monograph
regard
felin
leukaemia
vaccin
inactiv
number
percentag
anim
posit
felv
antigen
time
point
togeth
total
number
percentag
anim
treatment
group
persist
antigenaemia
summaris
tabl
month
studi
group
tabl
month
studi
group
tabl
month
studi
group
treatment
group
water
inject
six
individu
cat
seen
posit
felv
antigen
one
occas
administr
felv
viral
challeng
studi
day
six
anim
four
met
criteria
persist
antigenaemia
remain
five
cat
neg
felv
antigen
throughout
period
assess
thu
rate
persist
infect
felv
four
cat
cat
enrol
group
versifel
felv
one
anim
observ
posit
felv
antigen
postchalleng
cat
posit
sampl
occas
studi
day
inclus
therefor
met
criteria
persist
antigenaemia
thu
group
cat
treat
versifel
felv
develop
sign
infect
felv
viru
treatment
success
rate
four
five
kitten
enrol
receiv
treatment
observ
posit
felv
antigen
post
challeng
sampl
occas
therefor
four
anim
met
criteria
persist
antigenaemia
group
water
inject
six
cat
posit
felv
antigen
day
three
week
challeng
six
three
cat
remain
posit
felv
antigen
end
studi
anim
treatment
group
five
met
criteria
persist
antigenaemia
cat
enrol
group
versifel
felv
one
die
challeng
analysi
serum
remain
cat
indic
two
posit
felv
antigen
three
week
challeng
thereaft
remain
neg
studi
complet
cat
neg
throughout
studi
overal
none
cat
met
criteria
persist
antigenaemia
consequ
consid
treatment
success
six
kitten
enrol
group
receiv
treatment
posit
felv
antigen
occas
serum
sampl
collect
consequ
six
cat
treatment
group
met
criteria
persist
antigenaemia
treatment
group
water
inject
one
cat
euthanas
studi
day
dyskinesia
ten
cat
remain
one
posit
felv
antigen
studi
day
three
week
challeng
remain
posit
remaind
studi
ten
cat
treatment
group
one
met
criteria
persist
antigenaemia
treatment
group
versifel
felv
one
cat
die
studi
day
anoth
euthanas
studi
day
neither
relat
felv
diseas
remain
cat
none
posit
felv
antigen
studi
day
three
week
challeng
remain
neg
end
studi
overal
none
cat
treatment
group
met
criteria
persist
antigenaemia
consequ
anim
consid
treatment
success
kitten
control
group
treatment
six
kitten
posit
felv
antigen
studi
day
three
week
challeng
four
remain
posit
sampl
point
end
studi
two
kitten
neg
studi
day
consequ
six
cat
treatment
group
met
criteria
persist
antigenaemia
thu
valid
challeng
phase
studi
summari
antibodi
titr
geometr
mean
shown
tabl
ten
cat
group
antibodi
titr
day
one
cat
titr
na
na
na
na
na
na
na
na
na
na
na
na
na
na
na
na
day
prior
challeng
day
although
consid
anomal
neg
felv
antigen
sampl
time
point
cat
group
seroneg
day
day
three
antibodi
titr
consid
seroposit
group
geometr
mean
two
cat
antibodi
titr
return
day
third
titr
two
cat
neg
day
titr
day
possibl
indic
slowli
develop
antibodi
respons
six
cat
group
seroneg
day
antibodi
titr
cat
group
antibodi
titr
studi
day
although
one
cat
latter
time
point
titr
nine
cat
remain
antibodi
titr
studi
day
one
cat
titr
eight
cat
titr
studi
day
one
cat
titr
anoth
titr
five
cat
antibodi
titr
studi
day
one
cat
titr
two
cat
titr
two
cat
titr
cat
group
seroneg
studi
day
antibodi
titr
studi
day
three
week
post
complet
primari
vaccin
cours
three
cat
antibodi
titr
therefor
consid
seroposit
group
geometr
mean
studi
day
two
remain
cat
antibodi
titr
group
geometr
mean
studi
day
three
remain
cat
antibodi
titr
group
geometr
mean
studi
day
two
cat
antibodi
titr
group
geometr
mean
studi
day
two
cat
antibodi
titr
group
geometr
mean
six
cat
group
seroneg
studi
day
antibodi
titr
although
variat
bodi
weight
cat
descript
data
summari
show
littl
appar
differ
within
individu
studi
adult
control
vaccin
cat
measur
period
around
vaccin
period
associ
felv
challeng
descript
data
summari
show
littl
appar
differ
within
individu
studi
adult
control
vaccin
cat
rectal
temperatur
measur
period
around
vaccin
period
associ
felv
challeng
studi
conduct
accord
requir
defin
european
pharmacopeia
monograph
regard
felin
leukaemia
vaccin
inactiv
evalu
protect
felv
challeng
provid
versifel
felv
extend
period
anim
slightli
younger
target
age
first
vaccin
versifel
felv
seven
eight
week
age
challeng
virul
felv
either
eight
month
month
month
vaccin
cours
thu
time
felv
challeng
cat
adult
group
age
approxim
month
month
month
old
kitten
group
approxim
three
four
month
old
monograph
specifi
success
challeng
studi
challeng
viru
must
epidemiolog
relev
isol
less
vaccin
cat
develop
persist
infect
control
cat
must
develop
persist
infect
refer
monograph
requir
none
three
studi
complet
success
even
though
use
vaccin
vaccin
group
show
persist
antigenaemia
thu
could
consid
vaccin
offer
full
protect
subsequ
challeng
virul
felv
timescal
studi
observ
offset
fact
adult
control
anim
studi
succumb
challeng
infect
suffici
number
maximum
anim
month
durat
studi
show
persist
antigenaemia
given
felv
challeng
administ
cat
approxim
month
age
like
degre
age
relat
immun
felv
infect
may
factor
low
rate
persist
antigenaemia
unvaccin
cat
age
relat
resist
felv
challeng
report
previous
consequ
result
unexpect
inde
one
studi
hoover
other
show
rapid
decreas
suscept
experiment
infect
felv
newborn
kitten
abl
infect
compar
cat
age
month
year
old
recent
studi
compar
felv
vaccin
efficaci
challeng
cat
consider
smaller
dose
volum
titr
achiev
persist
antigenaemia
seven
eight
control
well
five
eight
vaccin
cat
seven
month
age
high
rate
antigenaemia
observ
addit
kitten
control
group
approxim
week
age
subject
felv
challeng
older
cat
time
provid
evid
chosen
dose
rout
administr
felv
materi
result
effect
aggress
challeng
anomal
antibodi
result
seen
two
cat
treatment
group
studi
day
may
rais
question
whether
cat
might
expos
extran
felv
post
vaccin
period
consid
extrem
unlik
observ
made
minor
cat
similar
result
observ
group
two
vaccin
day
either
remain
seroneg
seroposit
one
occas
post
vaccin
furthermor
cat
group
remain
healthi
throughout
prechalleng
period
confirm
neg
antigen
test
variou
interv
prior
challeng
cat
obtain
specifi
pathogen
free
spf
facil
hous
biosecur
categori
facil
throughout
durat
studi
would
therefor
extrem
unlik
extran
felv
viru
could
gain
access
facil
product
viral
envelop
gene
specif
major
envelop
protein
thought
involv
viru
host
rang
recognit
function
also
major
target
antibodymedi
viru
neutralis
howev
antibodi
gener
induc
follow
vaccin
observ
appear
correl
find
seen
studi
suggest
besid
antibodi
seroconvers
addit
immunolog
factor
cellmedi
immun
consid
vaccineinduc
durat
immun
felv
inde
studi
shown
role
cellmedi
immun
protect
felv
flynn
other
show
follow
vaccin
cat
felv
dna
vaccin
contain
gagpol
env
gene
felv
glasgow
strain
higher
level
virusspecif
effector
cytotox
lymphocyt
peripher
blood
lymphoid
organ
observ
unvaccin
control
persist
viraem
cat
appar
absenc
viraemia
cat
follow
vaccin
versifel
felv
vaccin
felv
antigen
could
detect
serum
sampl
follow
challeng
mean
infect
prevent
clinic
observ
show
enlarg
lymph
node
indic
felvrel
diseas
studi
shown
asymptomat
phase
infect
sever
clinic
sign
observ
cat
show
mild
stomat
gingiv
diarrhoea
mild
weight
loss
similar
observ
current
studi
correl
protect
low
level
viru
neutralis
antibodi
seen
small
number
vaccin
cat
observ
report
previous
recent
studi
examin
immun
felv
induc
vaccin
varieti
inactiv
virus
two
vaccin
found
protect
subsequ
challeng
effect
contain
viru
occur
despit
minim
detect
viru
neutralis
antibodi
seen
conclus
shown
although
agerel
resist
infect
virul
felv
challeng
evid
earli
month
age
vaccin
versifel
felv
help
protect
cat
felv
relat
diseas
three
year
primari
vaccin
kitten
